Resolution of the Council of Excperts (16th June, 2022): Therapy of gouty arthritis with an IL-1 inhibitor (anakinra)

1. Nasonov EL, Samsonov MYu. The role of interleukin 1 in the development of human diseases: Focus on Anakinra (IL-1 receptor antagonist). Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2022;60(3): 280-298 (In Russ.)]. doi: 10.47360/1995-4484-2022-280-298

2. Kineret (package insert). Thousand Oaks (CA):Amgen Inc.;2001.

3. Nasonov EL, Eliseev MS. Role of interleukin 1 in the development of human diseases. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2016;54(1): 60-77 (In Russ.)]. doi: 10.14412/1995-4484-2016-60-77

4. FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res (Hoboken). 2020;72(6):744-760. doi: 10.1002/acr.24180

5. Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castañeda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017; 76(1):29-42. doi: 10.1136/annrheumdis-2016-209707

6. So A, De Smedt T, Revaz S, Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther. 2007;9(2):R28. doi: 10.1186/ar2143

7. Chen K, Fields T, Mancuso CA, Bass AR, Vasanth L. Anakinra’s efficacy is variable in refractory gout: Report of ten cases. Semin Arthritis Rheum. 2010;40(3):210-214. doi: 10.1016/j.semarthrit.2010.03.001

8. Ghosh P, Cho M, Rawat G, Simkin PA, Gardner GC. Treatment of acute gouty arthritis in complex hospitalized patients with anakinra. Arthritis Care Res (Hoboken). 2013;65(8):1381-1384. doi: 10.1002/acr.21989

9. Ottaviani S, Moltó A, Ea HK, Neveu S, Gill G, Brunier L, et al. Efficacy of anakinra in gouty arthritis: A retrospective study of 40 cases. Arthritis Res Ther. 2013;15(5):R123. doi: 10.1186/ar4303

10. Van Wabeke J, Dhondt E, Peene I, Piette Y. Anakinra in resistant gout: A case report. Acta Clin Belg. 2017;72(4):293-295. doi: 10.1080/17843286.2016.1239891

11. Aouba A, Deshayes S, Frenzel L, Decottignies A, Pressiat C, Bienvenu B, et al. Efficacy of anakinra for various types of crystalinduced arthritis in complex hospitalized patients: A case series and review of the literature. Mediators Inflamm. 2015;2015:792173. doi: 10.1155/2015/792173

12. Thueringer JT, Doll NK, Gertner E. Anakinra for the treatment of acute severe gout in critically ill patients. Semin Arthritis Rheum. 2015;45(1):81-85. doi: 10.1016/j.semarthrit.2015.02.006

13. Vitale A, Cantarini L, Rigante D, Bardelli M, Galeazzi M. Anakinra treatment in patients with gout and type 2 diabetes. Clin Rheumatol. 2015;34(5):981-984. doi: 10.1007/s10067-014-2601-7

14. Janssen CA, Oude Voshaar MAH, Vonkeman HE, Jansen TLTA, Janssen M, Kok MR, et al. Anakinra for the treatment of acute gout flares: A randomized, double-blind, placebo-controlled, active-comparator, non-inferiority trial. Rheumatology (Oxford). 2019 Jan 2. doi: 10.1093/rheumatology/key402

15. Eliseev MS, Cheryomushkina EV, Krasnenko SO, Aristova MV. Use of anakinra in treatment of combination of calcium pyrophosphate deposition desease and gout (clinical observation). Medical Alphabet. 2022;15(9)6:14-19 (In Russ.)]. doi: 10.33667/2078-5631-2022-15-14-19

16. Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J. Goutassociated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440(7081):237-241. doi: 10.1038/nature04516

17. Rider P, Carmi Y, Guttman O, Braiman A, Cohen I, Voronov E, et al. IL-1α and IL-1β recruit different myeloid cells and promote different stages of sterile inflammation. J Immunol. 2011;187(9):4835-4843. doi: 10.4049/jimmunol.1102048

18. Boraschi D, Italiani P, Weil S, Martin MU. The family of the interleukin-1 receptors. Immunol Rev. 2018;281(1):197-232. doi: 10.1111/imr.12606

19. Dinarello CA. Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol Rev. 2018;281(1):8-27. doi: 10.1111/imr.12621

20. Roberge CJ, de Médicis R, Dayer JM, Rola-Pleszczynski M, Naccache PH, Poubelle PE. Crystal-induced neutrophil activation. V. Differential production of biologically active IL-1 and IL-1 receptor antagonist. J Immunol. 1994;152(11):5485-5494.

21. Pascart T, Norberciak L, Ea HK, Graf S, Guggenbuhl P, Lioté F. Difficult-to-treat gout flares: Eligibility for interleukin-1 inhibition in private practice is uncommon according to current EMA approval. Rheumatology (Oxford). 2019;58(12):2181-2187. doi: 10.1093/rheumatology/kez203

22. Arnold DD, Yalamanoglu A, Boyman O. Systematic review of safety and efficacy of IL-1-targeted biologics in treating immune-mediated disorders. Front Immunol. 2022;13:888392. doi: 10.3389/fimmu.2022.888392

23. Eliseev MS, Barskova VG, Nasonov EL. Canakinumab (an interleukin 1β inhibitor) is a breakthrough in the possibilities of anti-inflammatory therapy for gout. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2013;51(4):428-431 (In Russ.)]. doi: 10.14412/1995-4484-2013-1255

24. So A, De Meulemeester M, Pikhlak A, Yücel AE, Richard D, Murphy V, et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study. Arthritis Rheum. 2010;62(10): 3064-3076. doi: 10.1002/art.27600

25. Schlesinger N, De Meulemeester M, Pikhlak A, Yücel AE, Richard D, Murphy V, et al. Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat gouty arthritis by suppressing inflammation: Results of a randomized, dose-ranging study. Arthritis Res Ther. 2011; 13(2):R53. doi: 10.1186/ar3297

26. Schlesinger N, Alten RE, Bardin T, Schumacher HR, Bloch M, Gimona A, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: Results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis. 2012;71(11):1839-1848. doi: 10.1136/annrheumdis-2011-200908

27. van Poppel PC, van Asseldonk EJ, Holst JJ, Vilsbøll T, Netea MG, Tack CJ. The interleukin-1 receptor antagonist anakinra improves first-phase insulin secretion and insulinogenic index in subjects with impaired glucose tolerance. Diabetes Obes Metab. 2014;16(12):1269-1273. doi: 10.1111/dom.12357

28. Ruscitti P, Berardicurti O, Cipriani P, Giacomelli R; TRACK study group. Benefits of anakinra versus TNF inhibitors in rheumatoid arthritis and type 2 diabetes: Long-term findings from participants furtherly followed-up in the TRACK study, a multicentre, open-label, randomised, controlled trial. Clin Exp Rheumatol. 2021;39(2):403-406. doi: 10.55563/clinexprheumatol/phsqg7

29. Loustau C, Rosine N, Forien M, Ottaviani S, Juge PA, Lioté F, et al. Effectiveness and safety of anakinra in gout patients with stage 4–5 chronic kidney disease or kidney transplantation: A multicentre, retrospective study. Joint Bone Spine. 2018;85(6):755-760. doi: 10.1016/j.jbspin.2018.03.015

30. Everett BM, MacFadyen JG, Thuren T, Libby P, Glynn RJ, Ridker PM. Inhibition of Interleukin-1β and reduction in atherothrombotic cardiovascular events in the CANTOS trial. J Am Coll Cardiol. 2020;76(14):1660-1670. doi: 10.1016/j.jacc.2020.08.011

31. Solomon DH, Glynn RJ, MacFadyen JG, Libby P, Thuren T, Everett BM, et al. Relationship of interleukin-1β blockade with incident gout and serum uric acid levels: Exploratory analysis of a randomized controlled trial. Ann Intern Med. 2018;169(8):535-542. doi: 10.7326/M18-1167

32. Khani E, Shahrabi M, Rezaei H, Pourkarim F, Afsharirad H, Solduzian M. Current evidence on the use of anakinra in COVID-19. Int Immunopharmacol. 2022;111:109075. doi: 10.1016/j.intimp.2022.109075